TABLE 3.
Patient demographics and clinical characteristicsa
| Demographic or characteristicb | Rejected group (n = 67) | Accepted group (n = 34) | P value |
|---|---|---|---|
| Age (median [range]) (yr) | 10.0 (0.01–98.0) | 6.3 (0.01–76.0) | 0.172 |
| Department | 0.129 | ||
| Pediatrics | 56 (84) | 29 (85) | 0.824 |
| Neonatal | 5 (8) | 3 (9) | 0.811 |
| Obstetrics/gynecology | 8 (12) | 5 (15) | 0.757 |
| Hospitalization in past 30 days | 47 (70) | 19 (56) | 0.154 |
| Broad-spectrum antibiotic use in past 30 days | |||
| Prior admission | 29 (43) | 4 (12) | <0.001 |
| Prior 1st review | 40 (59) | 9 (26) | <0.001 |
| Immunocompromisedc | 38 (57) | 21 (64) | 0.508 |
| Previous ESBL or MDRO colonization and/or infection | 29 (43) | 11 (32) | 0.288 |
| Hypotension requiring fluid boluses and/or inotropes | 21 (31) | 4 (12) | 0.031 |
| Respiratory support | 19 (28) | 8 (24) | 0.203 |
| Oxygen | 4 (6) | 1 (3) | |
| Noninvasive ventilation | 1 (2) | 3 (9) | |
| Invasive | 14 (21) | 4 (12) | |
| Intensive care/high-dependency unit admission | 23 (34) | 9 (27) | 0.422 |
| Febrile neutropenia | 27 (40) | 13 (38) | 0.841 |
| Infection source | 0.348 | ||
| Systemic, culture positive | 34 (51) | 14 (41) | |
| Systemic, culture negative | 8 (12) | 7 (21) | |
| Gastrointestinal | 7 (10) | 7 (21) | |
| Genitourinary | 7 (10) | 3 (9) | |
| Respiratory | 8 (12) | 1 (3) | |
| Skin and soft tissue | 2 (3) | 1 (3) | |
| Multiple infections | 1 (2) | 0 (0) | |
| Prophylaxis | 0 (0) | 1 (3) | |
| ESBL-resistant organism identified | 12 (44) | 5 (33) | 0.482 |
a
Data are presented as number (%), unless otherwise indicated.
b
ESBL, extended-spectrum beta-lactamase; MDRO, multidrug-resistant organism (resistant to three or more antimicrobial classes).
c
Immunocompromised includes those undergoing a transplant, who had malignancy/receipt of chemotherapy, or who had immunodeficiency disorders.